Sofia, Bulgaria, October 4, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (the Company, SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that following its growth strategy and its goal of becoming a stronger regional player, the Company initiates a transaction for acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products in the following therapeutic areas: Sex hormones and modulators of the genital system, Urologicals and Antivirals for systemic use.